Theravance Biopharma reported third‑quarter 2025 results that exceeded analyst expectations, with total revenue of $20.0 million—up 2.08% versus the $19.58 million consensus estimate—and an adjusted earnings per share of $0.04, a $0.07 improvement over the $‑0.03 estimate, representing a 233% earnings surprise.
The company’s flagship product, YUPELRI, generated net sales of $71.4 million, a 15% year‑over‑year increase driven by a 6% rise in customer demand and a favorable channel mix that lifted net pricing. Hospital channel volume grew 29% YoY, contributing to the record profitability reported for the brand.
Theravance also confirmed that it has reached non‑GAAP breakeven for the quarter, a milestone that underscores disciplined cost management and robust commercial performance. Management indicated that the company expects to maintain breakeven‑level margins in the fourth quarter.
In the pipeline arena, the company announced that enrollment in the Phase III CYPRESS trial of ampreloxetine was completed in August 2025 and that topline data are expected in the first quarter of 2026. The trial’s outcome is viewed as a potential catalyst for future growth.
The balance sheet remains strong, with $333 million in cash and no debt. Theravance is on track to receive milestone payments from its Viatris partnership and a $50 million milestone from Royalty Pharma in the fourth quarter, further supporting its financial flexibility.
Overall, the earnings beat, YUPELRI growth, and pipeline progress reinforce Theravance’s trajectory toward sustained profitability and market expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.